Search

EHA-GBMTA-AHA Hematology Tutorial

EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

Sponsor prospectus

Dear Partner,

Welcome to the digital EHA Sponsor Prospectus 2024-2025. Over the past two years, the world of congresses, meetings, and education has drastically changed.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

Support for Research

Research in hematology is critical to improving our understanding of diseases, clinical practice, and overall patient care. Support for research in hematology is a priority for EHA, including for our European Affairs team.

Read more